Published in Proc Natl Acad Sci U S A on January 27, 2009
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature (2013) 2.22
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
How genetically engineered mouse tumor models provide insights into human cancers. J Clin Oncol (2011) 1.43
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 1.37
Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res (2010) 1.36
Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia (2011) 1.32
PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One (2010) 1.15
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013) 1.08
Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol (2010) 1.08
Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog (2013) 1.07
Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol (2009) 1.05
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. Mol Cancer Ther (2009) 1.04
Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget (2011) 1.03
Impact of heat-shock protein 90 on cancer metastasis. Future Oncol (2009) 1.00
Methylation profiling in individuals with uniparental disomy identifies novel differentially methylated regions on chromosome 15. Genome Res (2010) 0.97
Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res (2011) 0.92
Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. J Biol Chem (2010) 0.92
Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Sci Rep (2013) 0.90
FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget (2015) 0.88
Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature. Oncogene (2011) 0.87
Breast cancer genomes--form and function. Curr Opin Genet Dev (2010) 0.85
Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice. BMC Cancer (2013) 0.84
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. Genes Cancer (2011) 0.81
Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS One (2011) 0.81
Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies. Front Endocrinol (Lausanne) (2015) 0.80
Genomic analyses as a guide to target identification and preclinical testing of mouse models of breast cancer. Toxicol Pathol (2010) 0.80
Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer (2012) 0.78
Indole-3-carbinol disrupts estrogen receptor-alpha dependent expression of insulin-like growth factor-1 receptor and insulin receptor substrate-1 and proliferation of human breast cancer cells. Mol Cell Endocrinol (2012) 0.78
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol (2014) 0.77
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS One (2014) 0.77
Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism. Oncotarget (2014) 0.76
Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget (2017) 0.76
Non-coding single nucleotide variants affecting estrogen receptor binding and activity. Genome Med (2016) 0.75
CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy. Breast Cancer Res (2016) 0.75
Autocrine IGF1 Signaling Mediates Pancreatic Tumor Cell Dormancy in the Absence of Oncogenic Drivers. Cell Rep (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
The hallmarks of cancer. Cell (2000) 113.05
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell (2007) 6.44
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
The multistep nature of cancer. Trends Genet (1993) 6.12
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
Triple negative tumours: a critical review. Histopathology (2008) 4.94
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Triple-negative breast cancer: therapeutic options. Lancet Oncol (2007) 4.80
Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol (2007) 4.67
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res (2004) 2.90
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics (2006) 2.86
Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol (1994) 2.65
Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A (1993) 2.58
Mammary epithelial cells undergo secretory differentiation in cycling virgins but require pregnancy for the establishment of terminal differentiation. Development (1995) 2.50
Genetics of mouse growth. Int J Dev Biol (1998) 2.08
Conditional mutagenesis in mice with heat shock promoter-driven cre transgenes. Mamm Genome (2000) 1.71
Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res (2004) 1.50
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res (1987) 1.49
The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist (2008) 1.32
The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets (2005) 1.31
Demystifying basal-like breast carcinomas. J Clin Pathol (2007) 1.22
Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia (2006) 1.22
The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer (2007) 1.20
The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol (2007) 1.18
Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene (2001) 1.18
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene (2007) 1.10
The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res (2006) 1.09
The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun (2007) 1.08
The ras signaling pathway in mammary tumorigenesis and metastasis. J Mammary Gland Biol Neoplasia (2001) 1.07
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer (2007) 1.00
Classification of mouse mammary tumors in Dunn's miscellaneous group including recently reported types. J Natl Cancer Inst (1979) 0.99
Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. Clin Cancer Res (2005) 0.94
c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer (1991) 0.93
'Designer' tumors in mice. Oncogene (2004) 0.90
Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: identification of a specific insulin-responsive promoter element. Biochem Biophys Res Commun (2007) 0.90
Medicinal chemistry approaches to target the kinase activity of IGF-1R. IDrugs (2006) 0.86
Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras. Oncogene (2000) 0.85
Thermal chemistry of podophyllotoxin in ethanol and a comparison of the cytostatic activity of the thermolysis products. J Pharm Sci (1986) 0.77
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Deciphering the transcriptional histone acetylation code for a human gene. Cell (2002) 8.96
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell (2012) 4.88
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol (2005) 4.00
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat Immunol (2006) 3.48
Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell (2005) 2.98
Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A (2006) 2.92
A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (2013) 2.86
Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Nat Genet (2012) 2.75
Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science (2009) 2.51
Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res (2010) 2.25
BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science (2011) 2.17
BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res (2008) 2.06
Proliferation and migration of label-retaining cells of the kidney papilla. J Am Soc Nephrol (2009) 1.99
Testis determination requires insulin receptor family function in mice. Nature (2003) 1.94
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest (2002) 1.93
HMGA2 is a driver of tumor metastasis. Cancer Res (2013) 1.66
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 1.63
Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol (2004) 1.59
Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol (2002) 1.53
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J (2004) 1.35
Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J Neurosci (2003) 1.31
Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol (2006) 1.31
The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A (2008) 1.31
RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol (2008) 1.29
The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int J Cancer (2007) 1.27
The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci U S A (2008) 1.25
Overgrowth of a mouse model of the Simpson-Golabi-Behmel syndrome is independent of IGF signaling. Dev Biol (2002) 1.24
Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat (2011) 1.22
CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology (2006) 1.20
Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J (2004) 1.19
Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J (2004) 1.18
Notch, Myc and breast cancer. Cell Cycle (2007) 1.16
Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol (2005) 1.08
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther (2011) 1.07
Role of IGF signaling in olfactory sensory map formation and axon guidance. Neuron (2008) 1.04
Independent regulation of skeletal growth by Ihh and IGF signaling. Dev Biol (2006) 1.03
Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem (2002) 1.02
The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun (2004) 1.02
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) (2012) 1.01
Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes (2012) 1.01
The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression. J Cell Biol (2013) 1.00
The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes (2011) 1.00
Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis (2003) 1.00
A mouse model of uterine leiomyosarcoma. Am J Pathol (2004) 0.99
Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice. Diabetes (2012) 0.97
Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat (2009) 0.97
Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma. Arch Surg (2003) 0.97
PEG10 is a c-MYC target gene in cancer cells. Cancer Res (2006) 0.97
Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma. Cancer Res (2012) 0.97
PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol (2011) 0.96
Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med (2008) 0.96
Mosaic analysis of insulin receptor function. J Clin Invest (2004) 0.95
Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis (2006) 0.95
Molecular epidemiologic studies of polycyclic aromatic hydrocarbon-DNA adducts and breast cancer. Environ Mol Mutagen (2002) 0.95
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest (2014) 0.94
Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev (2004) 0.94
Genetic analysis of type-1 insulin-like growth factor receptor signaling through insulin receptor substrate-1 and -2 in pancreatic beta cells. J Biol Chem (2010) 0.94
Immunohistochemical analysis for cytokeratin 7, KIT, and PAX2: value in the differential diagnosis of chromophobe cell carcinoma. Am J Clin Pathol (2007) 0.94
Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet (2008) 0.93
Mesoscale phase distribution in single particles of LiFePO4 following lithium deintercalation. Chem Mater (2013) 0.91
Isolation of native human monoclonal autoantibodies to breast cancer. Hybrid Hybridomics (2002) 0.91
The origin of high electrolyte-electrode interfacial resistances in lithium cells containing garnet type solid electrolytes. Phys Chem Chem Phys (2014) 0.91
'Designer' tumors in mice. Oncogene (2004) 0.90
Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors. Environ Health Perspect (2009) 0.90
Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev (2002) 0.88
Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol (2003) 0.86
Cancer outcomes at the Hufeland (complementary/alternative medicine) klinik: a best-case series review. Integr Cancer Ther (2005) 0.86
Characterization of electrode materials for lithium ion and sodium ion batteries using synchrotron radiation techniques. J Vis Exp (2013) 0.86
Cyclin D1 overexpression is associated with estrogen receptor expression in Caucasian but not African-American breast cancer. Anticancer Res (2005) 0.85
The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study. Epigenetics (2011) 0.84
SDF-1 activates papillary label-retaining cells during kidney repair from injury. Am J Physiol Renal Physiol (2012) 0.84
Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Res Treat (2012) 0.84
P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res (2005) 0.84
Effect of surface microstructure on electrochemical performance of garnet solid electrolytes. ACS Appl Mater Interfaces (2015) 0.84